The DOI matches its Crossref record.
Effects of aging and liver disease on disposition of lorazepam
Abstract
The disposition of lorazepam after intravenous administration (2 mg) was investigated in patients with alcoholic cirrhosis and acute viral hepatitis, and compared to that in normal subjects ranging in age from 15 to 73 yr. No statistically significant age‐dependent relationships in the drug's pharmacokinetic parameters were observed. Cirrhosis was associated with a doubling of the mean elimination half‐life (21.7 ± 7.6 to 41.2 ± 24.5 hr). This was due to a similar increase in the volume of distribution of lorazepam, caused by a reduction in the extent of the drug's plasma binding (88.6 ± 2.5 from 93.2 ± 1.8). No changes in systemic plasma clearance of either the unbound (about 11 ml/min/kg) or bound plus unbound (about 0.75 ml/min/kg) lorazepam, or urinary recovery of conjugated drug (about 50%) were detected. In contrast, there were no significant changes in the kinetics of lorazepam in the patients with acute viral hepatitis. Comparison of lorazepam's systemic plasma clearance in the liver disease patients in whom studies with antipyrine and chlordiazepoxide had also been performed indicated impairment in their values but this was not the case for lorazepam. It is concluded that the degree of impairment, if any, in the metabolism of lorazepam in patients with liver disease is considerably less than that of certain other drugs including related benzodiazepines. Aging also does not lead to alterations either in distribution or metabolism as have been observed with other benzodiazepines. It is speculated that these observations may reflect characteristics of the drugs associated with their metabolic fate, i.e., glucuronidation or oxidative biotransformation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mangoni, A. A., & Jackson, S. H. D. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.02007.x · Cited by 1,874
Pharmacokinetics and dosage adjustment in patients with renal dysfunction
Verbeeck, R. K., & Musuamba, F. T. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0678-8 · Cited by 717
Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
Verbeeck, R. K. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0553-z · Cited by 652
Greenblatt (1982) · doi:10.1056/nejm198205063061804 · Cited by 584
Midazolam and Other Benzodiazepines
Olkkola, K. T., & Ahonen, J. (2008) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-74806-9_16 · Cited by 488
Metadata
- Authors
- Kraus, J. W., Desmond, P. V., Marshall, J. P., Johnson, R. F., Schenker, S., & Wilkinson, G. R.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1978-10
- Volume
- 24
- Issue
- 4
- Pages
- 411-419
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2336990701
- Cited by
- 252
- References
- 0
- FWCI
- 11.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of aging and liver disease on disposition of lorazepam. https://app.cochat.ai/papers/10.1002/cpt1978244411
- The paper
- Kraus, J. W., Desmond, P. V., Marshall, J. P., Johnson, R. F., Schenker, S., & Wilkinson, G. R. (1978). Effects of aging and liver disease on disposition of lorazepam. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt1978244411
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.